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Metastatic cancer is associated with a hypercoagulable state, and pathological venous
thromboembolic disease is a significant source of morbidity and the second leading cause
of death in patients with cancer. Here we aimed to develop a novel labeling strategy
to detect and quantify procoagulant circulating tumor cells (CTCs) from patients with
metastatic cancer. We hypothesize that the enumeration of procoagulant CTCs may be
prognostic for the development of venous thrombosis in patients with cancer. Our approach
is based on the observation that cancer cells are capable of initiating and facilitating cell-
mediated coagulation in vitro, whereby activated coagulation factor complexes assemble
upon cancer cell membrane surfaces. Binding of fluorescently labeled, active site-inhibited
coagulation factors VIIa, Xa, and IIa to the metastatic breast cancer cell line, MDA-MB-231,
non-metastatic colorectal cell line, SW480, or metastatic colorectal cell line, SW620, was
characterized in a purified system, in anticoagulated blood and plasma, and in plasma under
conditions of coagulation.We conclude that a CTC labeling strategy that utilizes coagulation
factor-based fluorescent probes may provide a functional assessment of the procoagulant
potential of CTCs, and that this strategy is amenable to current CTC detection platforms.
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INTRODUCTION
Cancer is a hypercoagulable state. Patients with cancer have a 4-
to 10-fold increased risk of developing thrombosis, which is a
significant source of morbidity and mortality for patients with
cancer (Trousseau, 1865; Baron et al., 1998; Sorensen et al., 2000;
Rickles and Levine, 2001; Falanga and Marchetti, 2009). Recurrent
thrombosis can be clinically managed with anticoagulant therapy;
however, the risk of bleeding complications associated with the
use of anticoagulants has prevented routine prophylactic antico-
agulation for patients with cancer who have not yet developed
thrombosis (Akl et al., 2011). Therefore, a method to identify
which cancer patients are at imminent risk to develop throm-
bosis would allow for an objective means by which to administer
personalized anticoagulant prophylaxis, reducing the morbidity,
and mortality for patients with cancer. There is currently a lack of
laboratory assays capable of identifying which patients with cancer
are at risk of developing thrombosis.
Blood coagulation is actuated by a system of serine proteases
that are contained within the blood in their inactive, zymogen
form. In health, activation of coagulation is restricted to sites of
blood vessel injury through the localized exposure of tissue fac-
tor (TF), a transmembrane protein constitutively expressed by
extravascular tissue not normally exposed to the circulating blood.
As blood hemorrhages from an injured vessel, it comes into con-
tact with TF-expressing cells outside of the vasculature. TF serves
as the membrane receptor and protein cofactor of coagulation
factor VIIa (FVIIa). The TF·FVIIa complex initiates the extrinsic
blood coagulation pathway by activating factor X (FX) and factor
IX (FIX). Activated factor X (FXa) and activated factor IX (FIXa)
are initially inhibited by TF pathway inhibitor (TFPI) present in
blood at a low concentration (∼2.4 nM) by forming a quaternary
FXa·TF·FVIIa·TFPI complex (Baugh et al., 1998; Lu et al., 2004).
FIXa forms the tenase complex with its protein cofactor FVIIIa
on the surface of phosphatidylserine (PS)-containing cell mem-
branes in the presence of calcium ion, which generates additional
FXa. FXa produced on PS-containing cell membranes assembles,
in a Ca2+-dependent manner, the prothrombinase complex with
its protein cofactor factor Va (FVa). The prothrombinase complex
converts prothrombin (FII) into thrombin (FIIa). FIIa cleaves fib-
rinogen into self-polymerizing, insoluble fibrin to form a plug at
the injury site, effectively stemming blood loss. The localization of
the procoagulant stimulus to the injury site, as well as anticoagu-
lant effects of the endothelium downstream of the injury, serve to
localize blood coagulation to the site of injury. However, patho-
logically excessive coagulation, or the initiation of coagulation at
sites other than blood vessel injury, can result in thrombosis.
Hematogenous spread of metastatic cancer requires tumor cells
to intravasate into blood vessels to navigate the bloodstream and
establish distant metastases. The existence of tumor cells in the
blood of patients with cancer has been known for over a century
(Ashworth, 1869), yet only recently has technology allowed the
routine cytological detection of these cells, hereafter referred to as
circulating tumor cells (CTCs). CTCs have been demonstrated to
be prognostic for overall patient survival, yet the impact of CTCs
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on cancer associated hypercoagulability has not been established
(Cristofanilli et al., 2004; Danila et al., 2007; Cohen et al., 2008;
de Bono et al., 2008). In vitro, cancer cell lines added to plasma
are able to induce coagulation. The ability of cancer cell lines to
clot plasma is abrogated by incubating with a TF-blocking anti-
body, or with Annexin V, which blocks the binding of coagulation
factors to the PS-containing cancer cell membrane (Berny-Lang
et al., 2011). Further, the clotting kinetics for plasma spiked with
cancer cells is strongly dependent upon the number of cells added
(Tormoen et al., 2011; Yates et al., 2011; Welsh et al., 2012). There-
fore, it appears that cancer cells are wholly capable of cell-mediated
coagulation in vitro, whereby they can initiate coagulation through
surface expression of TF and facilitate the propagation of coagu-
lation by binding and assembling coagulation factor complexes
upon their cell membranes.
The ability for CTCs to facilitate coagulation in human dis-
ease has not been investigated, primarily due to the previously
formidable technical challenge of identifying CTCs in the blood.
Technological advancements have allowed the reliable detection of
CTCs in patients with cancer through immunofluorescent label-
ing; specifically, cells that are cytokeratin positive, CD45 negative,
and nucleated as apparent with DAPI staining are currently utilized
to identify CTCs. On this basis, we sought to develop a functional
probe that is amenable to fluorescence microscopic techniques
to supplement CTC identification with the ability to characterize
the procoagulant nature of CTCs. In this study, we characterized
the binding of fluorescently labeled, active site-inhibited coagula-
tion factors VIIa, Xa, and IIa to the metastatic breast cancer cell
line, MDA-MB-231, non-metastatic colorectal cell line, SW480, or
metastatic colorectal cell line, SW620, in a purified system and
in blood plasma. Our approach is modeled after the presumed
requirement for procoagulant cells to bind coagulation factors
from plasma and subsequently assemble coagulation enzyme com-
plexes on their surface to facilitate cell-mediated coagulation. We
focused on coagulation factors in the TF-pathway of coagulation
based upon the in vitro results demonstrating the TF- and phos-
phatidylserine (PS)-dependent pathways by which cancer cells
mediate coagulation. We hypothesize that the identification and
enumeration of procoagulant CTCs will be prognostic for venous
thrombosis in patients with cancer.
MATERIALS AND METHODS
All reagents were purchased from Sigma or previously described
sources (Berny-Lang et al., 2011). The function-blocking anti-
factor XIa antibody 1A6 was obtained as previously described
(Tucker et al., 2009). H-Gly-Pro-Arg-Pro-OH (GPRP) was pur-
chased from Calbiochem.
FLUORESCENT PROBES AND REAGENTS
Fluorescein isothiocyante (FITC)-conjugated TF monoclonal
antibody was purchased from LifeSpan Bioscences. Human coag-
ulation factors VIIa, Xa, IIa, and fluorescein-conjugated d-Phe-
Pro-Arg-chloromethyl ketone (PPACK) were purchased from
Haematologic Technologies (Essex Junction, VT, USA).
Coagulation factors were incubated with the fluorophore-
conjugated PPACK as previously specified (Bock, 1992; Panizzi
et al., 2006). In brief, active site inactivation was verified by
comparing PPACK-bound coagulation factor activity toward the
chromogenic substrates Spectrozyme FVIIa, Spectrozyme Xa, or
Spectrozyme TH (American Diagnostica). Following inactivation,
excess PPACK was removed by dialysis using a Slide-A-Lyzer®
MINI Dialysis Unit (Thermo Scientific) with 5 mM Hepes and
0.15 M NaCl (pH= 7.40).
CELL CULTURE
The metastatic breast cancer cell line, MDA-MB-231, non-
metastatic colorectal cell line, SW480, and metastatic colorectal
cell line, SW620, were obtained from American Type Cell Cul-
ture. Cells were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) containing 10% fetal bovine serum (Gibco) and main-
tained in a controlled environment at 37˚C with 5% CO2/air
atmosphere. Prior to each experiment, cells were detached from
the culture flask by immersing in TrypLE Express (Gibco) for
20 min at 37˚C, followed by resuspension in complete media,
pelleted by subjecting to centrifugation at 210× g for 5 min fol-
lowed by final resuspension in serum-free DMEM. Resuspended
cell concentrations were measured with a hemocytometer.
HUMAN BLOOD AND PLASMA
Blood samples were obtained and managed in accordance with
Oregon Health and Science University Review Board approval.
Human whole blood was collected from healthy volunteers by
venipuncture into 1:9 v/v 3.2% sodium citrate. Platelet poor
plasma (PPP) was obtained similarly, except that the collected
blood was then subjected to centrifugation step at 2150× g for
10 min, followed by removing the supernatant and mixing with
the supernatant from two other donors. The pooled supernatant
was then subjected to a second centrifugation step at 2150× g for
10 min. The supernatant (PPP) was then removed, divided into
1 mL aliquots and stored at−80˚C prior to use.
ISOLATION OF PERIPHERAL BLOOD CELLS
To isolate human neutrophils, blood was collected 1:9 into 3.8%
sodium citrate, followed by a 1:7 dilution into citrate-phosphate-
dextrose as previously described (Itakura et al., 2011). In brief, 5 ml
of blood suspension was layered over 5 ml of Polymorphprep and
subjected to centrifugation at 500× g for 45 min. The neutrophil
band was extracted and diluted in Hank’s Balanced Salt Suspen-
sion (HBSS) to 50 ml, and subjected to centrifugation at 400× g
for 10 min. The supernatant was removed and the remaining cell
pellet was resuspended in sterile water for 30 s, followed by diluting
in 10 mL of 10X PIPES buffer (250 mM piperazine-N,N ′bis [2-
ethanesulfonic acid], 1.1 mM NaCl, 50 mM KCl, pH= 7.40), then
the volume increased to 50 mL with HBSS, and subjected to a final
centrifugation step at 400× g for 10 min. Cells were counted with
a hemocytometer and diluted to a final concentration of 106/mL.
To isolate human platelets, blood was collected as above
but then subjected to centrifugation at 200× g for 20 min as
previously described (White-Adams et al., 2009). In brief, the
supernatant containing plasma and platelets was incubated with
0.10µg/mL of prostacyclin and subjected to centrifugation at
1000× g for 10 min. The platelet pellet was resuspended in mod-
ified Tyrode’s buffer (129 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM
KCl, 12 mM NaHCO3, 20 mM HEPES, 5 mM glucose, 1 mM
MgCl2; pH= 7.30).
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CLOTTING TIMES
MDA-MB-231, SW480 or SW620 cells were diluted from 3× 106
to 1.5× 103 cells/ml in serum-free DMEM. Next, 50µL of cell
suspension or vehicle (DMEM) was mixed with 50µL of PPP for
180 s at 37˚C. Then, 50µL of 25 mM CaCl2 was added and the time
required for the plasma to clot was measured on a KC4 coagulation
analyzer (Trinity Biotech, Bray, Co., Wicklow, Ireland). To deter-
mine the mechanism of the cancer cell procoagulant activity, 50µL
of 3× 105 cells/mL were pretreated with a function-blocking anti-
TF mAb (50µg/mL) or the phosphatidylserine function-blocking
ligand Annexin V (20µg/mL) for 5 min at room temperature prior
to mixing with plasma. Further, PPP was pretreated with the FXa
inhibitor Rivaroxaban (20µg/mL) for 5 min prior to mixing with
cells.
Experiments were performed in duplicate and the average clot-
ting time reported. Clotting time experiments were repeated 3–9
times and plotted as mean± the standard error of the mean. Sta-
tistically significant differences were evaluated using a Student’s
T tests with Bonferroni’s correction against untreated cells ( for
p-value<0.05) or vehicle (∗ for p-value<0.05).
FLOW CYTOMETRY
One-hundred thousand MDA-MB-231 or SW620 cells were sus-
pended in 50µl of PBS, PPP, or PPP treated with the anti-
FXI antibody 1A6 (12.5µg/mL) and the fibrin polymeriza-
tion inhibitor Gly-Pro-Arg-Pro-OH (GPRP 10 mM), and 8.3 mM
CaCl2 (final concentration). Cell suspensions were incubated
with fluorescently labeled coagulation factors FVIIa (50–500 nM),
FXa (100–5000 nM) or FIIa (100-10000 nM), or FITC-conjugated
anti-TF (10–100µg/mL) for 30 min at room temperature. Then
labeled cells were diluted to 500µL with PBS and characterized
using a FACS Calibur flow cytometer with CellQuest Pro acquisi-
tion and analysis software (Becton Dickinson, Franklin Lakes, NJ,
USA) as previously described (McCarty et al., 2002).
STATIC ADHESION
Coverslips (#1.5 12 mm; Fischer Scientific) were etched for
30 s in a 70% nitric acid bath, immersed in deionized H20
(R= 18.2 MΩ.cm), rinsed in ethanol, and allowed to air dry.
Etched and dried coverslips were then placed in individ-
ual wells of a 24-well plate. Five hundred µL of 4% 3-
aminopropyltriexothysilane in ethanol was added to the wells
and allowed to coat for 2 min. Coverslips were then washed
once in ethanol and submerged in H20 prior to performing the
experiments.
Three hundred thousand MDA-MB-231, SW480, or SW620
cells in serum-free DMEM were dispensed onto the etched cov-
erslips and allowed to adhere for 60 min at 37˚C. Non-adherent
cells were removed by washing with PBS. Recalcified plasma con-
taining the anti-FXIa antibody 1A6 (12.5µg/mL) and 10 mM
GPRP was dispensed over immobilized cells and allowed to incu-
bate for 30 min at room temperature. Cells were washed in PBS,
and incubated with fluorescently labeled coagulation factors FVIIa
(500 nM), FXa (5µM), or FIIa (10µM) or FITC-conjugated anti-
TF mAB (50µg/mL) in PBS for 30 min at room temperature.
Labeled cells were washed in PBS, fixed with 3.7% paraformalde-
hyde, washed in triplicate, and mounted in Fluoromount G
(Southern Biotech) and kept at 4˚C overnight. Labeled, adher-
ent cells were imaged on a Zeiss Axiovert 200 M at 40× with a
Zeiss EC Plan-Neofluar 0.75 NA objective using fluorescence and
differential interference contrast (DIC) microscopy. A minimum
of three images were recorded from each experimental condition,
with representative images shown for each condition.
Binding of coagulation factors to purified populations of
peripheral blood cells was performed by dispensing 300µL of
cells onto silanized coverslips and allowing them to adhere for
60 min at 37˚C. Cells were then washed and incubated with PBS
(vehicle) or PBS containing active site-inhibited, fluorescent coag-
ulation factor probes for 30 min at room temperature. Cells were
then washed in PBS, fixed, and mounted as described above.
RESULTS
CLOTTING TIMES
To investigate whether the metastatic breast cancer cell line, MDA-
MB-231, non-metastatic colorectal cell line, SW480, or metastatic
colorectal cell line, SW620, were sufficient to initiate and propa-
gate blood coagulation, washed cells were suspended in serum-free
DMEM and added to recalcified human plasma. The subsequent
time required for the plasma to clot (i.e., clotting times) was mea-
sured as a function of cell count in a coagulometer (Figures 1A–C).
All three cancer cell lines hastened the time for plasma to clot as
compared to vehicle (DMEM) and the clotting times depended
upon the number of cancer cells added to the plasma. To deter-
mine the role for cancer cell-expressed TF in initiating clotting,
a function-blocking anti-TF mAb (50µg/mL) was added to the
cancer cells prior to mixing with plasma. Our results show that the
anti-TF mAb abrogated the ability for SW480 and SW620 cells to
clot plasma, and prolonged the clotting times for MDA-MB-231
cells (288.6 s vs. 38.5 s, respectively). We next designed experiments
to determine whether cancer cell surface exposed acidic phospho-
lipids were required for clotting. Cancer cells were pretreated with
Annexin V (20µg/mL), which binds to and functionally blocks
the ability for PS to bind clotting factors and assemble enzyme
complexes on a cell surface. Pretreating SW480 and SW620 cells
with Annexin V abrogated the ability of these cells to clot plasma.
Pretreatment of MDA-MB-231 cells with Annexin V prolonged
clotting times in a concentration-dependent manner (131.2 s at
20µg/mL vs. 229.1 s at 40µg/mL). Finally, pretreating the plasma
with the FXa inhibitor, Rivaroxaban, prior to mixing with the can-
cer cells completely abrogated the ability of the three cancer cell
lines tested to clot plasma. Taken together, our data demonstrate
that MDA-MB-231, SW480, and SW620 cells are procoagulant in
a TF, PS, FXa, and cell count dependent manner (Figures 1D–F).
FLOW CYTOMETRY OF LABELED CELLS
Labeling of cancer cells in a purified system
We next investigated whether fluorescently labeled, active site-
inhibited coagulation factors could be used to label procoagulant
cancer cells in a purified system. For this,we utilized the MDA-MB-
231 and SW620 cancer cell lines, as they were shown to have the
highest and lowest procoagulant activities of the cancer cell lines
we tested, respectively, and we aimed to determine if coagulation
factor-based probes could label both cell lines as well as contrast the
labeling efficacy between cell lines. MDA-MB-231 and SW620 cells
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FIGURE 1 | Clotting times for human plasma containing MDA-MB-231,
SW480, or SW620 cells. The addition of MDA-MB-231, SW480, and SW620
cells shortened clotting times of plasma in a cell count dependent manner.
(A–C) The ability for these cells to coagulate plasma was inhibited with a
function-blocking antibody to tissue factor (TF) or Annexin V, and completely
abrogated with a Factor Xa inhibitor. (D–F) Human sodium citrate
anticoagulated plasma was pretreated with vehicle or the FXa inhibitor
rivaroxaban for 5 min at room temperature. MDA-MB-231, SW480, or SW620
cells were pretreated with vehicle, a neutralizing antibody to TF (anti-TF,
50µg/mL) or the phosphatidylserine binding protein Annexin V (20µg/mL) for
5 min at room temperature. Cells and plasma were then mixed together for
3 min on a KC4 coagulation analyzer prior to recalcification to 8.3 mM (final
concentration). Clotting time experiments were performed in duplicate for
each condition and reported as the average. Each experiment was
independently repeated 3–9 times. Data are reported as mean±SEM.
*P <0.05 vs. the absence of cells. P <0.05 vs. vehicle pretreated cells.
were suspended in serum-free DMEM and incubated with either
vehicle or active site-blocked, fluorescently labeled FVIIa (50 nM),
FXa (0.5–5µM), or FIIa (0.5–10µM) for 30 min at room temper-
ature. Samples were diluted 10-fold in phosphate-buffered saline
(PBS) and fluorescence recorded with flow cytometry. Figure 2
shows the fluorescence intensity histogram for labeled cells vs.
vehicle treated controls. The surface expression of TF was verified
by staining of the cell lines with a FITC-conjugated anti-TF mAb
(data not shown).
Factor VIIa-labeling of MDA-MB-231 cells was clearly evi-
dent at 50 nM [mean fluorescence intensity (MFI)= 67 vs. 2.6
for unstained cells] and did not change at 100 nM (MFI= 72;
Figure 2A). Factor VIIa-labeling of SW620 cells was evident at
50 nM (MFI= 10 vs. 2.86 for unlabeled cells), with further MFI
increases observed at 100 and 500 nM (MFI= 16 and 88, respec-
tively; Figure 2B). FXa-labeling of MDA-MB-231 and SW620
cells was evident at 500 nM (MFI= 21.05 for MDA-MB-231 and
MFI= 33.31 for SW620), with further increases in fluorescence
intensity for labeling at 1 and 5µM (MFI= 49 and 324 for MDA-
MB-231, and MFI= 67 and 281 for SW620, respectively). FIIa
(thrombin) labeling of MDA-MB-231 cells was not apparent at
100 nM (MFI= 6.17) while SW620 cells (MFI= 9.91) were labeled
at 100 nM. MDA-MB-231 cells showed increases in labeling inten-
sity with FIIa-based probes from 500 nM to 10µM (MFI= 24,
42, 305, and 531 for 500 nM, 1, 5, and 10µM, respectively).
SW620 cells showed increases in labeling intensity from 500 nM
to 1µM (MFI= 37, 90, 282 for 500 nM, 1 and 5µM, respectively),
with no further increase seen at 10µM (MFI= 258). Labeling of
cancer cells in a purified system showed cell and factor-specific
characteristics for labeling efficacy. Our data show that a con-
centration of 50 nM FVIIa-based probe was sufficient to label
both the MDA-MB-231 and SW620 cells, while a concentration
of 500 nM of the FXa- or FIIa-based probes was required to label
both MDA-MB-231 and SW620 cells.
Labeling of cancer cells in human plasma
We next investigated whether fluorescently labeled coagulation
factors could be used to label procoagulant cancer cells in plasma.
For this, MDA-MB-231and SW620 cells were suspended in sodium
citrate anticoagulated PPP containing vehicle or fluorescently
labeled FVIIa (50–500 nM), FXa (0.5–5µM), or FIIa (0.5–10µM)
for 30 min at room temperature. Samples were diluted 10-fold
in PBS and fluorescence measured with flow cytometry. Figure 3
shows the fluorescence intensity histogram for labeled cells vs.
vehicle treated controls. The surface expression of TF was verified
by staining of the cell lines with a FITC-conjugated anti-TF mAb
(data not shown).
Factor VIIa-labeling of MDA-MB-231 cells in plasma was evi-
dent at 50 nM (MFI= 13.8 vs. 2.4 for unlabeled cells) and flu-
orescence labeling increased at probe concentrations of 100 nM
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FIGURE 2 | Characterization of fluorescent coagulation factor probe
binding to MDA-MB-231 and SW620 cells suspended in DMEM.
One-hundred thousand MDA-MB-231 (A) or SW620 cells (B) were incubated
with vehicle or fluorescently modified, active site-inhibited coagulation factors
FVIIa (10–500 nM), FXa (100–5000 nM), or FIIa (100–10,000 nM) for 30 min at
room temperature. Cells were then diluted 10-fold in sterile-filtered
phosphate-buffered saline (PBS, pH=7.40) and analyzed by flow cytometry.
Shaded histograms represent background fluorescence while white
histograms represent labeled cells at the fluorescent probe concentrations
shown.
(MFI= 18 and 81 for 100 and 500 nM, respectively; Figure 3A).
FVIIa-based probe labeling of SW620 cells was evident at 50 nM
(MFI= 11.7 vs. 2.8 for unlabeled cells) in plasma with a fur-
ther increases in fluorescence intensity at higher probe con-
centrations (MFI= 20 and 76 at 100 and 500 nM, respectively;
Figure 3B). Labeling of MDA-MB-231 cells with the FXa-based
probe in plasma was not evident at 100 nM (MFI= 3.9 vs. 2.4
for unlabeled cells), but could be seen at 500 nM (MFI= 11.3),
with further increases in fluorescence labeling at higher probe
concentrations (MFI= 18.9 and 74.2 for 1 and 5µM, respec-
tively). Labeling of SW620 cells with the FXa-based probe
in plasma was observed at 100 nM (MFI= 8.05 vs. 2.8 for
unlabeled cells) and increases in fluorescence intensity were
observed at higher probe concentrations (MFI= 22, 35, and 210
at 500 nM, 1 and 5µM, respectively). FIIa-labeling of MDA-
MB-231 cells was observed at 500 nM (MFI= 27 vs. 2.6 for
unlabeled cells) with further increases in fluorescence inten-
sity seen with probe concentration (MFI= 47, 321, and 515
for 1, 5, and 10µM, respectively). In contrast, the FIIa-probe
did not label SW620 cells at or below 1µM FIIa-probe con-
centration (MFI= 3.8, 4.2, and 6.8 for 100, 500, and 1000 nM,
respectively).
Labeling of cancer cells in plasma under conditions of coagulation
In the presence of a procoagulant stimulus, such as a procoag-
ulant cancer cell, coagulation factors in plasma undergo limited
proteolysis to become activated. In addition, the presence of Ca2+
ions may present Ca-dependent binding sites on cells which are
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FIGURE 3 | Characterization of fluorescent coagulation factor probe
binding to MDA-MB-231 and SW620 cells in human plasma. One-hundred
thousand MDA-MB-231 (A) or SW620 cells (B) were incubated with vehicle
or fluorescently modified, active site-inhibited coagulation factors FVIIa
(10–500 nM), FXa (100–5000 nM), or FIIa (100–10,000 nM) in 50µL of PPP for
30 min at room temperature. Cells were then diluted 10-fold in sterile-filtered
phosphate-buffered saline (PBS, pH=7.40) and analyzed by flow cytometry.
Shaded histograms represent background fluorescence while white
histograms represent labeled cells at the fluorescent probe concentrations
shown.
inaccessible in the presence of the anticoagulant, sodium citrate.
To determine if coagulation factor-based probes could be used to
label procoagulant cancer cells under conditions of coagulation,
cancer cells were suspended in PPP pretreated with an anti-FXIa
antibody and GPRP and recalcified to 8 mM Ca2+ containing vehi-
cle or fluorescently labeled FVIIa (50–500 nM), FXa (0.5–5µM),
or FIIa (0.5–10µM) for 30 min at room temperature. Figure 4
shows the fluorescence intensity histogram for labeled cells vs.
vehicle treated controls.
FVIIa-labeling of both cell types was evident at 50 nM (MDA-
MB-231 MFI= 102 vs. 2.4 for unlabeled cells (Figure 4A), SW620
MFI= 11.4 vs. 2.8 for unlabeled cells (Figure 4B), and increases
in FVIIa-based probe concentrations showed minimal effect on
MDA-MB-231 fluorescence intensity (MFI= 122 and 159 for
100 and 500 nM, respectively). SW620 cells exhibited increases
in fluorescence intensity with FVIIa-based probe concentrations
of 100 and 500 nM (MFI= 23.6 and 112.3, respectively). FXa-
labeling of MDA-MB-231 cells was seen at 500 nM (MFI= 15.5
vs. 2.4 for unlabeled cells), and the fluorescence intensity increased
with FXa-based probe concentration (MFI= 24 and 90 for 1 and
5µM, respectively). FXa-based probe labeling of SW620 cells was
seen at 500 nM (MFI= 27.3 vs. 2.8 for unlabeled cells) and further
increases in fluorescence intensity were seen at FXa-based probe
concentrations of 1 and 5µM, respectively. The FIIa-based probe
labeled SW620 cells at but not below 5µM (MFI= 21 vs. 2.8 for
unlabeled cells), while MDA-MB-231 cells were not clearly labeled
at 5µM under conditions of coagulation (MFI= 8.4 vs. 2.4 for
unlabeled cells).
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FIGURE 4 | Characterization of fluorescent coagulation factor probe
binding to MDA-MB-231 and SW620 cells in human plasma under
conditions of coagulation. One-hundred thousand MDA-MB-231 (A) or
SW620 cells (B) were incubated with vehicle or fluorescently modified, active
site-inhibited coagulation factors FVIIa (10–500 nM), FXa (100–5000 nM), or
FIIa (100–10,000 nM) in 50µL of recalcified PPP (8 mM, final Ca2+
concentration) containing the fibrin polymerization blocker GPRP (10 mM) and
the FXIa-blocking antibody 1A6 (12.5µg/mL) for 30 min at room temperature.
Cells were then diluted 10-fold in sterile-filtered phosphate-buffered saline
(PBS, pH=7.40) and analyzed by flow cytometry. Shaded histograms
represent background fluorescence while white histograms represent labeled
cells at the fluorescent probe concentrations shown.
IMAGING OF IMMOBILIZED CELLS
Labeling of immobilized cancer cells in a purified system
Due to the extreme rarity with which CTCs are present in the
blood of patients with cancer, flow cytometry is not routinely
utilized to detect CTCs. Rather, various plating or lab-on-chip
methods are utilized in combination with fluorescent labels to
identify and/or isolate CTCs from a population of cells that con-
sists of both normal blood cell constituents and CTCs (Nagrath
et al., 2007; Gleghorn et al., 2010; Marrinucci et al., 2012). We
designed a series of experiments to determine whether our label-
ing strategy was amenable to a cell processing protocol that utilizes
cancer cells being plated onto glass slides. We immobilized MDA-
MB-231, SW480, and SW620 cells on functionalized glass surfaces
and exposed them to fluorescently labeled FVIIa (500 nM), FXa
(5µM), FIIa (10µM). DIC, fluorescence, and merged images are
shown in Figure 5 for MDA-MB-231, SW480, and SW620 cells.
The images showed that the MDA-MB-231 cells were robustly
labeled with the FVIIa and FXa probes. The FVIIa and FXa probes
weakly labeled the SW480 cells and SW620 cells. The FIIa-probe
failed to label any of the three cell lines.
Labeling of immobilized cancer cells following exposure to plasma
under conditions of coagulation
Our next set of experiments were designed to determine whether
fluorescently labeled coagulation factor probes could label cells
that had been exposed to blood plasma under conditions of coag-
ulation. We immobilized MDA-MB-231, SW480, and SW620 cells
on functionalized glass surfaces, exposed the immobilized cells
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FIGURE 5 | Characterization of fluorescent coagulation factor probe
binding to immobilized MDA-MB-231, SW480, and SW620 cells in
DMEM. MDA-MB-231 (A), SW480 (B), and SW620 cells (C) were
immobilized on silanized glass slides prior to incubation with DMEM (vehicle)
or DMEM containing fluorescently labeled coagulation factors FVIIa (500 nM),
FXa (5µM), or FIIa (10µM) for 30 min at room temperature, washed in DMEM
and fixed in 3.7% paraformaldehyde. Immobilized cells were imaged using
differential interference contrast (DIC) and fluorescence microscopy.
FIGURE 6 | Characterization of fluorescent coagulation factor probe
binding to immobilized MDA-MB-231, SW480, and SW620 cells in
the presence of coagulation. MDA-MB-231 (A), SW480 (B), and
SW620 cells (C) were immobilized on silanized glass slides and
incubated with recalcified human plasma containing the anti-FXIa
antibody, 1A6, and the fibrin polymerization inhibitor, GPRP, for 30 min
at room temperature. Cells were then washed and treated with PBS
(vehicle) or PBS containing fluorescently labeled coagulation factors
FVIIa (500 nM), FXa (5µM), or FIIa (10µM) for 30 min at room
temperature, washed in PBS, and fixed in 3.7% paraformaldehyde.
Immobilized cells were imaged using differential interference contrast
(DIC) and fluorescence microscopy.
to recalcified plasma, and then incubated the slides with fluo-
rescently labeled FVIIa (500 nM), FXa (5µM), or FIIa (10µM).
DIC, fluorescence, and merged images are shown in Figure 6 for
MDA-MB-231, SW480, and SW620 cells. The images showed that
all coagulation factor-based probes labeled at least a portion of
the adherent cancer cells for all three cancer cell lines. The FVIIa
probe labeled all the adherent MDA-MB-231 cells. Heterogeneous
FVIIa-labeling was observed for both the SW480 and SW620 cell
lines, with some of the adherent cells labeling brightly, while other
cells on the same slide were not labeled by the FVIIa probe. The
FXa probe showed complete labeling of all three cell lines, but
pronounced heterogeneity in labeling was noted as some cells were
brightly labeled and others showed dim labeling by the FXa probe.
The FIIa-probe showed complete labeling of the MDA-MB-231
and SW620 cell lines and heterogeneous labeling of the SW480
cells.
Labeling of immobilized cancer cells in whole blood
Following our experiments in cell-free labeling buffers, we next
determined whether coagulation factor-based probes could be
used to label cancer cells in whole blood. Immobilized MDA-MB-
231, SW480, and SW620 cells were incubated with anticoagulated
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FIGURE 7 | Characterization of fluorescent coagulation factor probe
binding to immobilized MDA-MB-231, SW480, and SW620 cells in
whole blood. MDA-MB-231 (A), SW480 (B), and SW620 cells (C) were
immobilized on silanized glass slides and incubated with sodium citrate
anticoagulated whole blood (vehicle) containing fluorescently labeled
coagulation factors FVIIa (500 nM), FXa (5µM), FIIa (10µM), or
FITC-conjugated anti-TF mAb (50µg/mL) for 30 min at room temperature,
washed in PBS and fixed in 3.7% paraformaldehyde. Immobilized cells
were imaged using differential interference contrast (DIC) and
fluorescence microscopy.
whole blood containing either vehicle, or fluorescent, active site-
inhibited FVIIa (500 nM), FXa (5 µM), FIIa (10µM), or FITC-
conjugated anti-TF mAb (50µg/mL) for 30 min at room tem-
perature. DIC, fluorescence, and merged images are shown in
Figure 7. The FVIIa probe showed heterogeneous labeling of the
MDA-MB-231 cells, SW480, and SW620 cells, although the label-
ing of the SW480 cells was greatly diminished as compared to
cells which had been exposed to plasma under conditions of coag-
ulation (Figure 6). Heterogeneous labeling of all three cell lines
with the FXa and FIIa-probes was observed, with very few SW480
or SW620 cells labeled. All three cell lines were labeled with the
anti-TF mAb in whole blood.
Labeling of immobilized platelets and neutrophils
Following the reduced labeling of the MDA-MB-231 cells, SW480,
and SW620 cells in whole blood as compared to cell-free labeling
solutions, we designed a set of experiments to determine if periph-
eral blood cells might be binding the probe in solution, and thereby
causing diminished labeling of immobilized cancer cells. Neu-
trophils and platelets were purified from peripheral blood draws
and immobilized onto silanized glass slides, and incubated with
fluorescent FVIIa (500 nM), FXa (5µM), and FIIa (10µM). Coag-
ulation factor-based probes failed to bind immobilized peripheral
blood cells in a purified system (Figure 8). Our data show that
neither the FVIIa (500 nM), FXa (5µM), FIIa (10µM) probes
labeled purified human platelets (Figure 8A) or neutrophils
(Figure 8B). In a complementary experiment, addition of puri-
fied human neutrophils to plasma failed to reduce clotting times
(605.3 s vs. 672.7 s for vehicle and 105/mL neutrophils, respec-
tively) demonstrating that purified human neutrophils did not
exhibit a procoagulant phenotype. Similar fluorescent coagulation
factor labeling results were observed in whole blood (data not
shown).
DISCUSSION
Metastatic disease accounts for the majority of cancer deaths.
VTE events are significant contributors to metastatic disease, with
reports indicating 18% of cancer deaths resulting from VTE. For
instance, lung adenocarcinoma patients have an estimated 20-
fold higher risk for developing VTE than the general population;
however, not all patients develop VTE, making the bleeding risks
of anticoagulating the entire adenocarcinoma patient population
unacceptable. No current technology is available to objectively
predict patient risk for VTE in order to personalize anticoagu-
lant prophylaxis therapy. CTC counts have not been evaluated
as a potential biomarker for risk to develop cancer associated
thrombosis.
In this study, we demonstrate the use of fluorescently modi-
fied, active site-inhibited coagulation factors to label procoagulant
cancer cells. The metastatic breast cancer cell line, MDA-MB-231,
and metastatic colorectal cell line, SW620, were used due to the
fact that these cell lines possess the ability to survive circulation in
the blood to establish hematogenous metastases in murine models
of cancer metastasis (Zhang et al., 1991; Sampson-Johannes et al.,
1996). The non-metastatic colorectal cell line, SW480, was derived
from the primary tumor from the same individual from which
the SW620 was derived. We determined that all three cell lines
exhibited a procoagulant phenotype, with the MDA-MB-231 cells
resulting in the highest procoagulant activity, while the SW620
cells had the lowest procoagulant activity. The procoagulant activ-
ity of the MDA-MB-231, SW480, and SW620 cell lines could be
reduced or abrogated by a function-blocking antibody to TF, or
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FIGURE 8 | Characterization of fluorescent coagulation factor probe
binding to immobilized human neutrophils and platelets. Human
platelets (A) and neutrophils (B) were immobilized on silanized glass slides
and incubated with PBS (vehicle) containing fluorescently labeled coagulation
factors FVIIa (500 nM), FXa (5µM), or FIIa (10µM) for 30 min at room
temperature, washed in PBS and fixed in 3.7% paraformaldehyde.
Immobilized cells were imaged using differential interference contrast (DIC)
and fluorescence microscopy.
by pretreatment with Annexin V. Annexin V blocks the binding of
coagulation factors that contain γ-carboxyglutamic acid domains
(Gla domains) to PS on the cell membrane. These results support
the notion that TF and PS exposure is a general phenomenon seen
for cancer cell-mediated coagulation in vitro, and support a role
for CTC-mediated coagulation as a potential contributor to the
hypercoagulability seen for patients with cancer.
Previous studies have shown that cancer cell procoagulant
activity correlates better with PS exposure than with overall TF
expression levels, supporting a role for cell membrane effects in
regulating procoagulant activity as opposed to surface TF expres-
sion (Barrowcliffe et al., 2002; Pickering et al., 2004). Therefore,
we aim to develop a function-based CTC labeling strategy to
determine whether CTCs are procoagulant, and whether CTC enu-
meration and procoagulant characterization strategies are clini-
cally useful in predicting thrombosis in patients with cancer. We
hypothesized that coagulation factors themselves would serve as
specific, functional probes with which to identify procoagulant
cells. Our approach was based upon the requirement for coagu-
lation factors to for surface-assembled enzyme complexes on the
surfaces of procoagulant cells in order to catalyze intermediate
steps of the coagulation cascade. We focused on the coagulation
factors FVIIa, FXa, and FIIa, as they are key components of the
extrinsic (TF) pathway of coagulation.
Our results with flow cytometry show that the cancer cell
lines MDA-MB-231, SW480, and SW620 bind coagulation factor
probes. Immobilized cells show that cancer cells exhibited het-
erogeneity in their ability to bind various fluorescently modified
active site-inhibited coagulation factors. For instance, we observed
heterogeneous labeling of SW480 with the FVIIa probe in a both
a purified system and in whole blood. Binding heterogeneity was
observed over a range of probe concentrations (data not shown),
suggesting the heterogeneity was not due to a scarcity of probe con-
centration. Further, the K D for FVIIa to TF is in the pM range, five
orders of magnitude below our labeling concentration. A stronger
binding of FVIIa could suggest that these cells are more proco-
agulant than cells that show weak binding, however, currently no
method can be used to determine individual cell procoagulant
activity. Moreover, protease activated receptor 2 (PAR2) is another
known receptor for FVIIa besides TF. MDA-MB-231 and SW620
cells are known to express PAR2, while SW480 cells have been
shown to have little PAR2 surface expression (Morris et al., 2006;
Zhou et al., 2008). Whether coagulation factor probe binding levels
correlate with procoagulant activity or whether PAR2 expression
levels affect binding of FVIIa probe is a focus of future studies.
FIIa-based probes brightly labeled immobilized MDA-MB-231,
SW480, and SW620 cells in the presence of coagulation. In con-
trast, FIIa-probes only weakly labeled these cell lines in whole
blood and failed to label any cells in DMEM. One prominent dif-
ference between FIIa and the other coagulation factor probes is the
absence of the Gla domain for FIIa. The Gla domain mediates cal-
cium ion-dependent binding of vitamin K-dependent coagulation
factors to PS-containing procoagulant cell membranes. Calcium-
dependent binding may account for differences in the FVIIa or
FXa probe labeling as compared to FIIa in DMEM, which contains
calcium, but fails to account for differences in whole blood in the
presence of the calcium-chelator sodium citrate. As FIIa binds fib-
rinogen and fibrin, it is possible that FIIa labeled cancer cells that
are coated in fibrin, a phenomenon that would be expected after
exposing a procoagulant cancer cell to plasma under conditions
of coagulation. However, using flow cytometry, we observed label-
ing of cancer cells with a FIIa-based probe in purified systems,
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suggesting an alternate mechanism for binding of FIIa to the can-
cer cell surface. Our future work will be focused on identifying the
mechanism(s) of FIIa-cancer cell binding.
In this study, we demonstrated the use of fluorescently mod-
ified, active site-inhibited coagulation factors to label procoagu-
lant cancer cells. We demonstrated that coagulation factors based
probes bound to cancer cell lines in purified systems and in whole
blood, yet failed to bind to peripheral blood cells. Labeling of
cancer cells was demonstrated via flow cytometry in purified sys-
tems, as well as on an immobilized-cell platform similar to what
is currently used in some CTC detection platforms. This work
is the first step in the development of a function-based CTC
labeling strategy to determine whether CTCs are procoagulant,
and whether CTC enumeration and procoagulant characterization
strategies are clinically useful in predicting thrombosis in patients
with cancer.
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